Yubo International Biotech Ltd financial data

Symbol
YBGJ on OTC
Industry
Electromedical & Electrotherapeutic Apparatus
Location
Room 105, Building 5, 31 Xishiku Avenue, Beijing, China
State of incorporation
New York
Fiscal year end
December 31
Former names
MAGNA LAB INC (to 12/4/2020)
Latest financial report
10-Q - Q2 2024 - Aug 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 21.4 % -17.5%
Quick Ratio 5.26 % -34.2%
Debt-to-equity -189 % +54.4%
Return On Equity 80.6 % -20.9%
Return On Assets -88.7 % -175%
Operating Margin -309 % +9.74%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares
Entity Public Float 2.98M USD +4042%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 450K USD +88.2%
Operating Income (Loss) -1.39M USD -69.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.52M USD -85.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.52M USD -85.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.7K USD +45.3%
Inventory, Net 86.9K USD -59.1%
Assets, Current 761K USD +8.68%
Property, Plant and Equipment, Net 293K USD -44%
Operating Lease, Right-of-Use Asset 499K USD -11%
Intangible Assets, Net (Excluding Goodwill) 57.5K USD -2.14%
Assets 1.73M USD -11.9%
Liabilities, Current 3.95M USD +34%
Operating Lease, Liability, Noncurrent 197K USD +20.9%
Liabilities 4.15M USD +33.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 158K USD -6.67%
Retained Earnings (Accumulated Deficit) -5.79M USD -32.4%
Stockholders' Equity Attributable to Parent -2.52M USD -119%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.42M USD -110%
Liabilities and Equity 1.73M USD -11.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -120K USD -269%
Net Cash Provided by (Used in) Financing Activities 98K USD
Net Cash Provided by (Used in) Investing Activities -30K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.7K USD +322%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.7K USD +48.1%
Deferred Tax Assets, Valuation Allowance 1.29M USD +40.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.17 pure 0%
Operating Lease, Liability 499K USD
Payments to Acquire Property, Plant, and Equipment 18.9K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -535K USD -71.5%
Lessee, Operating Lease, Liability, to be Paid 518K USD -14%
Property, Plant and Equipment, Gross 336K USD -40%
Operating Lease, Liability, Current 302K USD -24.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 57.3K USD -79.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 290K USD +43.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 17K USD -83.3%
Deferred Tax Assets, Operating Loss Carryforwards 1.29M USD
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -102K USD -29.3%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 17K USD
Additional Paid in Capital 2.99M USD +1.85%
Operating Leases, Future Minimum Payments, Due in Two Years 843K USD +51.6%
Amortization of Intangible Assets 12.6K USD +12.4%
Depreciation, Depletion and Amortization 41.4K USD +167%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 2.67M USD -6.72%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Operating Leases, Future Minimum Payments, Due in Three Years 748K USD +34.5%
Interest Expense 17K USD +33233%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%